Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 6/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.39 |
| ▸ | GHSR | Q92847 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30878583 | 0.93 | CA12 (0.47) | PDK2CA12CA1CA2CA9 | |
| SCHEMBL30878565 | 0.87 | CA12 (0.48) | PDK2CA12CA1CA2CA9 | |
| SCHEMBL33532809 | 0.85 | ESR1 (0.41) | ESR1ESR2MTNR1BGHSR | |
| SCHEMBL30878631 | 0.84 | ESR1 (0.40) | ESR1ESR2MTNR1BGHSR | |
| SCHEMBL33530437 | 0.80 | DRD2 (0.46) | PDK2CA12CA1CA2CA9 | |
| SCHEMBL30878634 | 0.79 | SCN9A (0.44) | PDK2CA12CA1CA2CA9 | |
| SCHEMBL30878562 | 0.78 | ESR1 (0.57) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| SCHEMBL25722286 | 0.78 | ESR1 (0.57) | ESR1ESR2NQO2MTNR1AMTNR1B | |
| SCHEMBL33532142 | 0.75 | DRD2 (0.51) | CA12CA1CA2CA9 | |
| SCHEMBL30878574 | 0.74 | RIPK1 (0.49) | PDK2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
| EP-4587126-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024057021-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | PDK2 4424/4885CA12 4358/4885CA1 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.